Baseline insulin-like growth factor-1 (IGF-1) and stimulated peak growth hormone response can serve as predictors for how severe growth hormone deficiency is in pediatric patients as well as how these patients will respond to different treatments, according to a study recently published in the Journal of the Endocrine Society. Researchers led by Michael O. Thorner,...
The investigational long-acting, once-weekly prodrug lonapegsomatropin (TransCon hGH) may be more beneficial to treatment-naïve pediatric patients with growth hormone deficiency (GHD) than daily somatropin of equivalent weekly dose, according to a paper recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Aimee D. Shu, MD, of Ascendis Pharma (who funded the...
As high-tech innovations improve diabetes management, patients in underserved communities can often lag behind. Addressing the need for more education, Anne Peters, MD, spearheaded a new project that has created easy-to-read guides that make diabetes education easily understood by underserved populations. Type 1 diabetes is a challenging condition for any patient to manage, but it...
Hepatic steatosis — more commonly known as fatty liver disease — appears to have a disproportional effect on Hispanic Americans, with Mexican Americans at an even higher risk. A better understanding of these risk factors is crucial to creating better individualized care protocols for these patients. In 2018, the National Institute of Minority Health and...
The most common hormone disorder affecting women of reproductive age — polycystic ovary syndrome (PCOS) — cost an estimated $8 billion to diagnose and treat nationwide in 2020, according to a new economic analysis published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. PCOS is a common disorder characterized by irregular menstrual periods,...
It is believed that polycystic ovary syndrome (PCOS) can impact up to 10% of women but according to new genetic research presented in March at ENDO 2021, it can manifest in men as well. Endocrine News talks to the lead researcher, Jia Zhu, MD, about this somewhat surprising revelation as well as how this study...
A once-weekly injectable suspension has been approved in the U.S. for the treatment of type 2 diabetes. Marketed by AstraZeneca as BYDUREON BCise (exenatide extended-release), it has been shown to to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise. The approval by the US Food and...
ENDO 2021 presented a plethora of research detailing how COVID-19 impacted a number of endocrine comorbidities. However, two studies in particular took a closer look at how the virus impacted pediatric patients with type 1 diabetes. Each year, ENDO is something of an “embarrassment of riches” because it consists of four days packed with the...
As high-tech innovations improve diabetes management, patients in underserved communities can often lag behind. Addressing the need for more education, Anne Peters, MD, spearheaded a new project that has created easy-to-read guides that make diabetes education easily understood by underserved populations. Type 1 diabetes is a challenging condition for any patient to manage, but it...
Hepatic steatosis — more commonly known as fatty liver disease — appears to have a disproportional effect on Hispanic Americans, with Mexican Americans at an even higher risk. A better understanding of these risk factors is crucial to creating better individualized care protocols for these patients. In 2018, the National Institute of Minority Health and...
It is believed that polycystic ovary syndrome (PCOS) can impact up to 10% of women but according to new genetic research presented in March at ENDO 2021, it can manifest in men as well. Endocrine News talks to the lead researcher, Jia Zhu, MD, about this somewhat surprising revelation as well as how this study...
